You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 12, December 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Invited Critique
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Endocrine Surgery
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Estimated Risk of Pheochromocytoma Recurrence After Adrenal-Sparing Surgery in Patients With Multiple Endocrine Neoplasia Type 2A—Invited Critique

Quan-Yang Duh, MD

Arch Surg. 2006;141:1205.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

An ideal operation for a pheochromocytoma in a patient with multiple endocrine neoplasia type 2A (MEN 2A) would be to remove the pheochromocytoma and all of the medulla while saving the adrenal cortex. Residual medullary tissue can become hyperplastic or develop recurrent pheochromocytoma. The cortex is necessary for adrenocortical steroid production, and insufficient cortex causes Addison disease. The adrenal gland is like a peanut butter sandwich: the medulla is the peanut butter and the cortex, the bread. The ideal operation of removing all the peanut butter (medulla) but keeping the bread (cortex) is a nearly impossible task. In practice, cortex-sparing adrenalectomy is a compromise, weighing the risks of recurrent pheochromocytoma and adrenocortical insufficiency.

Most endocrine surgeons do not prophylactically resect a normal-appearing adrenal gland in patients with MEN 2, and many would attempt to spare the adrenal cortex when Addison disease is a significant risk. Thus, for . . . [Full Text of this Article]


AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Estimated Risk of Pheochromocytoma Recurrence After Adrenal-Sparing Surgery in Patients With Multiple Endocrine Neoplasia Type 2A
Reza Asari, Christian Scheuba, Klaus Kaczirek, and Bruno Niederle
Arch Surg. 2006;141(12):1199-1205.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.